It's a building around, it is a diversification ... But I think we have great teams within Biogen and we are able to really dissect these data sets to see whether we have enough confidence ...

Meanwhile, fellow Swiss company Novartis will no longer use diverse panels in its hiring process for U.S.-based employees, ...

There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.

Experts at the 2025 Clinical Trial Supply New England conference will discuss strategies for optimising clinical supply ...

Building tools for clinicians The explosion ... So, another effort from Biogen is a web-platform and app they’ve developed called Neurodiem, which helps CNS specialists specifically keep up ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

After bringing Zolgensma to market in 2019 as the first gene therapy for spinal muscular atrophy, Novartis is back with a ...

It’s not just American companies rethinking their diversity, equity, and inclusion (DEI) initiatives. Swiss pharma giants ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...

The Reserve Bank would like to state that the bank is well-capitalised and the financial position of IndusInd Bank remains ...